These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38685745)

  • 1. Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non-small cell lung cancer undergoing stereotactic body radiotherapy.
    Fang F; Jia Z; Xie H; Cao Y; Zhu X; Yang XY; Guo X; Zhang H
    Clin Respir J; 2024 May; 18(5):e13749. PubMed ID: 38685745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.
    Cannon NA; Meyer J; Iyengar P; Ahn C; Westover KD; Choy H; Timmerman R
    J Thorac Oncol; 2015 Feb; 10(2):280-5. PubMed ID: 25299234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
    Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of diffuse cancer inflammation index (ALI), serum neutrophil/lymphocyte (NLR) and platelet/lymphocyte (PLR) in advanced-stage lung cancer.
    Ozturk AE; Komurcuoglu B; Karakurt GK; Ozturk O
    J Cancer Res Ther; 2024 Apr; 20(3):893-897. PubMed ID: 38102903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy.
    Sebastian N; Wu T; Bazan J; Driscoll E; Willers H; Yegya-Raman N; Bond L; Dwivedi A; Mo X; Tan Y; Xu-Welliver M; Haglund K; Jabbour SK; Keane FK; Williams TM
    Radiother Oncol; 2019 May; 134():151-157. PubMed ID: 31005209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?
    Unal D; Eroglu C; Kurtul N; Oguz A; Tasdemir A
    Asian Pac J Cancer Prev; 2013; 14(9):5237-42. PubMed ID: 24175807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with inoperable locally advanced non-small-cell lung cancer.
    Sun S; Qu Y; Wen F; Yu H
    Biomark Med; 2020 Oct; 14(14):1341-1352. PubMed ID: 32808809
    [No Abstract]   [Full Text] [Related]  

  • 10. NLR, MLR, and PLR are adverse prognostic variables for sleeve lobectomy within non-small cell lung cancer.
    Han R; Zhang F; Hong Q; Visar D; Zhan C; Zhao C; Wang F; Zhang S; Li F; Li J; Mu J
    Thorac Cancer; 2024 Aug; 15(24):1792-1804. PubMed ID: 39034535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients.
    Cho A; Untersteiner H; Hirschmann D; Fitschek F; Dorfer C; Rössler K; Zöchbauer-Müller S; Gatterbauer B; Hochmair MJ; Frischer JM
    J Neurooncol; 2021 Jan; 151(2):257-265. PubMed ID: 33179214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Hepatocellular Carcinoma Treated with Stereotactic Body Radiotherapy.
    Park Y; Chang AR
    Korean J Gastroenterol; 2022 Jun; 79(6):252-259. PubMed ID: 35746839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy: a single-center large-cohort study.
    Abravan A; Salem A; Price G; Faivre-Finn C; van Herk M
    Acta Oncol; 2022 Feb; 61(2):163-171. PubMed ID: 34979860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
    Scilla KA; Bentzen SM; Lam VK; Mohindra P; Nichols EM; Vyfhuis MA; Bhooshan N; Feigenberg SJ; Edelman MJ; Feliciano JL
    Oncologist; 2017 Jun; 22(6):737-742. PubMed ID: 28533476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Pre-Treatment NLR and Other Hematologic Biomarkers on the Outcomes of Early-Stage Non-Small-Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy.
    Aduquaye M; Dube S; Bashir B; Chowdhury A; Ahmed N; Leylek A; Kim J; Lambert P; Bucher O; Hunter W; Sivananthan G; Koul R; Rathod S
    Curr Oncol; 2022 Jan; 29(1):193-208. PubMed ID: 35049693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer].
    Yi F; Gu Y; Chen S; Liu Y; Yin W; Zhang Y; Cao B
    Zhongguo Fei Ai Za Zhi; 2018 Jun; 21(6):481-492. PubMed ID: 29945708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic index score predicts outcome of patients with Stage I non-small cell lung cancer after stereotactic body radiation therapy.
    Shi S; Ye L; Zhao Q; Hu Y; Huang Y; Chen G; Zeng Z; He J
    Jpn J Clin Oncol; 2019 Apr; 49(4):367-372. PubMed ID: 30715411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can we define any marker associated with brain failure in patients with locally advanced non-small cell lung cancer?
    Sert F; Cosgun G; Yalman D; Ozkok S
    Cancer Radiother; 2021 Jun; 25(4):316-322. PubMed ID: 33422415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer.
    Rice SJ; Belani CP
    PLoS One; 2021; 16(12):e0260988. PubMed ID: 34855926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.